<SEC-DOCUMENT>0001209191-22-005437.txt : 20220128
<SEC-HEADER>0001209191-22-005437.hdr.sgml : 20220128
<ACCEPTANCE-DATETIME>20220128165157
ACCESSION NUMBER:		0001209191-22-005437
CONFORMED SUBMISSION TYPE:	4/A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20220118
FILED AS OF DATE:		20220128
DATE AS OF CHANGE:		20220128

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Deignan Charles A.
		CENTRAL INDEX KEY:			0001664690

	FILING VALUES:
		FORM TYPE:		4/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37783
		FILM NUMBER:		22569644

	MAIL ADDRESS:	
		STREET 1:		C/O CLEARSIDE BIOMEDICAL, INC.
		STREET 2:		1220 OLD ALPHARETTA ROAD, SUITE 300
		CITY:			ALPHARETTA
		STATE:			GA
		ZIP:			30005

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Clearside Biomedical, Inc.
		CENTRAL INDEX KEY:			0001539029
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				452437375
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		900 NORTH POINT PARKWAY
		STREET 2:		SUITE 200
		CITY:			ALPHARETTA
		STATE:			GA
		ZIP:			30005
		BUSINESS PHONE:		678-270-3631

	MAIL ADDRESS:	
		STREET 1:		900 NORTH POINT PARKWAY
		STREET 2:		SUITE 200
		CITY:			ALPHARETTA
		STATE:			GA
		ZIP:			30005
</SEC-HEADER>
<DOCUMENT>
<TYPE>4/A
<SEQUENCE>1
<FILENAME>doc4a.xml
<DESCRIPTION>FORM 4/A SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4/A</documentType>

    <periodOfReport>2022-01-18</periodOfReport>

    <dateOfOriginalSubmission>2022-01-20</dateOfOriginalSubmission>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001539029</issuerCik>
        <issuerName>Clearside Biomedical, Inc.</issuerName>
        <issuerTradingSymbol>CLSD</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001664690</rptOwnerCik>
            <rptOwnerName>Deignan Charles A.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O CLEARSIDE BIOMEDICAL, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>900 NORTH POINT PARKWAY, SUITE 200</rptOwnerStreet2>
            <rptOwnerCity>ALPHARETTA</rptOwnerCity>
            <rptOwnerState>GA</rptOwnerState>
            <rptOwnerZipCode>30005</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Financial Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2022-01-18</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>46250</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>362699</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>2.19</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2022-01-18</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>138750</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2032-01-18</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>138750</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>138750</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">These shares are represented by restricted stock units (&quot;RSUs&quot;). Each RSU represents a contingent right to receive one share of common stock of the Issuer. The shares underlying the RSU vest in 4 equal annual installments on each of January 18, 2023, January 18, 2024, January 18, 2025 and January 18, 2026, subject to the Reporting Person's continuous service as of each such vesting date.</footnote>
        <footnote id="F2">One-fourth of the shares underlying this option vest on January 18, 2023 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such vesting date.</footnote>
    </footnotes>

    <remarks>This amendment to the Reporting Person's Form 4 filed with the Securities and Exchange Commission on January 20, 2022 is being filed to correct the total number of stock options and restricted stock units awarded to the Reporting Person on January 18, 2022. Based on the foregoing, the total number of shares beneficially owned following the reported transactions should have been 353,866 instead of 351,366.</remarks>

    <ownerSignature>
        <signatureName>/s/ Mark Ballantyne, Attorney-in-Fact</signatureName>
        <signatureDate>2022-01-28</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
